These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
372 related items for PubMed ID: 35543733
41. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis. Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, Tay KJ, Tuan J, Thang SP, Lam W, Yuen J, Lawrentschuk N, Hofman MS, Murphy DG, Chen K. Eur Urol; 2023 Jul; 84(1):36-48. PubMed ID: 37032189 [Abstract] [Full Text] [Related]
42. Significance of metabolic tumor volume and total lesion uptake measured using Ga-68 labelled prostate-specific membrane antigen PET/CT in primary staging of prostate cancer. Kubilay E, Akpinar Ç, Oǧuz ES, Araz MS, Soydal Ç, Baltacı S, Ürün Y, Süer E. Urol Oncol; 2022 Sep; 40(9):408.e19-408.e25. PubMed ID: 35902300 [Abstract] [Full Text] [Related]
43. The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer. Meijer D, Ettema RH, van Leeuwen PJ, van der Kwast TH, van der Poel HG, Donswijk ML, Oprea-Lager DE, Bekers EM, Vis AN. BJU Int; 2023 Mar; 131(3):330-338. PubMed ID: 36069585 [Abstract] [Full Text] [Related]
44. Diagnostic accuracy of 18F-fluciclovine PET/CT in primary lymph node staging of prostate cancer. Hoekstra RJ, Beulens A, Vrijhof EHJEJ, Wyndaele DNJ, Roef M, Brouwer LJM, Somford DM, Sedelaar M, van Basten JA. Nucl Med Commun; 2021 May 01; 42(5):476-481. PubMed ID: 33323869 [Abstract] [Full Text] [Related]
45. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H, Beer AJ, Schwaiger M, Eiber M. J Urol; 2016 May 01; 195(5):1436-1443. PubMed ID: 26682756 [Abstract] [Full Text] [Related]
46. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients. Poulsen MH, Bouchelouche K, Høilund-Carlsen PF, Petersen H, Gerke O, Steffansen SI, Marcussen N, Svolgaard N, Vach W, Geertsen U, Walter S. BJU Int; 2012 Dec 01; 110(11):1666-71. PubMed ID: 22520686 [Abstract] [Full Text] [Related]
47. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology. Yaxley JW, Raveenthiran S, Nouhaud FX, Samartunga H, Yaxley AJ, Coughlin G, Delahunt B, Egevad L, McEwan L, Wong D. J Urol; 2019 Apr 01; 201(4):815-820. PubMed ID: 30672842 [Abstract] [Full Text] [Related]
48. A retrospective study assessing the accuracy of [18F]-fluorocholine PET/CT for primary staging of lymph node metastases in intermediate and high-risk prostate cancer patients undergoing robotic-assisted laparoscopic prostatectomy with extended lymph node dissection. Puterman C, Bjöersdorff M, Amidi J, Anand A, Soller W, Jiborn T, Kjölhede H, Trägårdh E, Bjartell A. Scand J Urol; 2021 Aug 01; 55(4):293-297. PubMed ID: 33939583 [Abstract] [Full Text] [Related]
49. Head-to-Head Comparison of 18F-PSMA-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging with Whole-mount Histopathology as Reference in Localisation and Staging of Primary Prostate Cancer. Exterkate L, Hermsen R, Küsters-Vandevelde HVN, Prette JF, Baas DJH, Somford DM, van Basten JA. Eur Urol Oncol; 2023 Dec 01; 6(6):574-581. PubMed ID: 37230883 [Abstract] [Full Text] [Related]
51. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. Eur Urol Focus; 2018 Sep 01; 4(5):686-693. PubMed ID: 28753806 [Abstract] [Full Text] [Related]
52. Comparing the Diagnostic Performance of Multiparametric Prostate MRI Versus 68Ga-PSMA PET-CT in the Evaluation Lymph Node Involvement and Extraprostatic Extension. Arslan A, Karaarslan E, Güner AL, Sağlıcan Y, Tuna MB, Kural AR. Acad Radiol; 2022 May 01; 29(5):698-704. PubMed ID: 32768351 [Abstract] [Full Text] [Related]
53. Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy. Du X, Dong Y, Liu J, Su Y, Zhu Y, Pan J, Dong B, Chen R, Liu J, Tong Z, Pienta KJ, Rowe SP, Dong L, Xue W. Prostate; 2023 Aug 01; 83(11):1112-1120. PubMed ID: 37165552 [Abstract] [Full Text] [Related]
54. Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE). Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF, LIGHTHOUSE Study Group. Eur Urol; 2023 Oct 01; 84(4):361-370. PubMed ID: 37414702 [Abstract] [Full Text] [Related]
55. Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. Sprute K, Kramer V, Koerber SA, Meneses M, Fernandez R, Soza-Ried C, Eiber M, Weber WA, Rauscher I, Rahbar K, Schaefers M, Watabe T, Uemura M, Naka S, Nonomura N, Hatazawa J, Schwab C, Schütz V, Hohenfellner M, Holland-Letz T, Debus J, Kratochwil C, Amaral H, Choyke PL, Haberkorn U, Sandoval C, Giesel FL. J Nucl Med; 2021 Feb 01; 62(2):208-213. PubMed ID: 32817141 [Abstract] [Full Text] [Related]
56. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography. Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, Lotz J, Schildhaus HU, Trojan L, Sahlmann CO. Prostate; 2015 Dec 01; 75(16):1934-40. PubMed ID: 26356236 [Abstract] [Full Text] [Related]
57. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni NM, Salonia A, Colombo R, Freschi M, Rigatti P, Montorsi F. Eur Urol; 2012 Jun 01; 61(6):1132-8. PubMed ID: 22099610 [Abstract] [Full Text] [Related]
59. High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation. Rahman LA, Rutagengwa D, Lin P, Lin M, Yap J, Lai K, Mancuso P, Rathore P, Haghighi K, Gassner P, Wong LH, Lalak N. Cancer Imaging; 2019 Dec 11; 19(1):86. PubMed ID: 31829288 [Abstract] [Full Text] [Related]
60. 68Ga-PSMA PET/CT compared with MRI/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study. Petersen LJ, Nielsen JB, Langkilde NC, Petersen A, Afshar-Oromieh A, De Souza NM, De Paepe K, Fisker RV, Arp DT, Carl J, Haberkorn U, Zacho HD. World J Urol; 2020 Apr 11; 38(4):939-948. PubMed ID: 31190153 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]